Cercar
24/01/2023
The 2019 and 2021 International workshops on Alport syndrome (vol 30, 507, 2022)
Daga S., Ding J., Deltas C., Savige J., Lipska-Zietkiewicz B.S., Hoefele J., Flinter F., Gale D.P., Aksenova M., Kai H., Perin L., Barua M., Torra R., Miner J.H., Massella L., Ljubanovic D.G., Lennon R., Weinstock A.B., Knebelmann B., Cerkauskaite A., Gear S., Gross O., Turner A.N., Baldassarri M., Pinto A.M., Renieri A.. The 2019 and 2021 International workshops on Alport syndrome (vol 30, 507, 2022). EUROPEAN JOURNAL OF HUMAN GENETICS. 2023; 32(1)DOI:10.1038/s41431-023-01286-z. PMID:36690832. IF:3.700(Q2/3D).
09/01/2023
The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants
Sánchez R., Ripoll-Vera T., López-Mendoza M., de Juan-Ribera J., Gimeno J.R., Hermida Á., Ruz-Zafra M.A., Torregrosa J.V., Mora A., García-Pinilla J.M., Fortuny E., Aguinaga-Barrilero A., Torra R.. The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants. Orphanet Journal of Rare Diseases. 2023; 18(1)DOI:10.1186/s13023-022-02599-w. PMID:36624527. IF:3.400(Q2/4D).
01/12/2022
Effects of Bardoxolone Methyl in Alport Syndrome
Warady, BA, Pergola, PE, Agarwal, R, Andreoli, S, Appel, GB, Bangalore, S, Block, GA, Chapman, AB, Chin, MP, Gibson, KL, Goldsberry, A, Iijima, K, Inker, LA, Kashtan, CE, Knebelmann, B, Mariani, LH, Meyer, CJ, Nozu, K, O'Grady, M, Rheault, MN, Silva, AL, Stenvinkel, P, Torra, R, Chertow, GM. Effects of Bardoxolone Methyl in Alport Syndrome. Clinical Journal of the American Society of Nephrology. 2022; 17(12)DOI:10.2215/CJN.02400222. PMID:36411058. IF:9.800(Q1/1D).
07/11/2022
Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study
Hernandez, D, Vazquez-Sanchez, T, Sola, E, Lopez, V, Ruiz-Esteban, P, Caballero, A, Salido, E, Leon, M, Rodriguez, A, Serra, N, Rodriguez, C, Facundo, C, Perello, M, Silva, I, Marrero-Miranda, D, Cidraque, I, Moreso, F, Guirado, L, Seron, D, Torres, A. Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study. BMC Nephrology. 2022; 23(1)DOI:10.1186/s12882-022-02989-z. PMID:36344929. IF:2.300(Q3/7D).
01/11/2022
Digenic Alport Syndrome
Savige, J, Renieri, A, Ars, E, Daga, S, Pinto, AM, Rothe, H, Gale, DP, Aksenova, M, Cerkauskaite, A, Bielska, O, Lipska-Zietkiewicz, B, Gibson, JT. Digenic Alport Syndrome. Clinical Journal of the American Society of Nephrology. 2022; 17(11)DOI:10.2215/CJN.03120322. PMID:35675912. IF:9.800(Q1/1D).
01/11/2022
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression
Quiroga, B, Torra, R. Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression. Nutrients. 2022; 14(21)DOI:10.3390/nu14214651. PMID:36364911. IF:5.900(Q1/2D).
01/11/2022
Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell
Bover, J, Trinidad, P, Jara, A, Soler-Majoral, J, Martin-Malo, A, Torres, A, Frazao, J, Urena, P, Dusso, A, Arana, C, Graterol, F, Romero, G, Troya, M, Samaniego, D, D'Marco, L, Valdivielso, JM, Fernandez, E, Arenas, MD, Torregrosa, V, Navarro-Gonzalez, JF, Lloret, MJ, Ballarin, JA, Bosch, RJ, Gorriz, JL, de Francisco, ALM, Gutierrez, O, Ara, J, Felsenfeld, A, Canalejo, A, Almaden, Y. Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell. NEFROLOGIA. 2022; 42(6)DOI:10.1016/j.nefro.2021.12.005. PMID:36925324. IF:2.600(Q3/6D).
28/10/2022
Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study
Winterbottom, J, Simms, RJ, Caroli, A, Cornec-Le Gall, E, Demoulin, N, Furlano, M, Meijer, E, Devuyst, O, Gansevoort, RT, Le-Meur, Y, Perico, N, Torra, R, Ong, ACM. Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. Clinical Kidney Journal. 2022; 15(11)DOI:10.1093/ckj/sfac144. PMID:36825031. IF:4.600(Q1/2D).